Last reviewed · How we verify
glucose 20%
Glucose 20% is a hypertonic dextrose solution that provides rapid carbohydrate substrate for energy metabolism and increases blood glucose concentration.
Glucose 20% is a hypertonic dextrose solution that provides rapid carbohydrate substrate for energy metabolism and increases blood glucose concentration. Used for Acute hypoglycemia (symptomatic or severe), Caloric supplementation in parenteral nutrition, Adjunctive treatment in hyperkalemia (shifts potassium intracellularly).
At a glance
| Generic name | glucose 20% |
|---|---|
| Sponsor | Universitair Ziekenhuis Brussel |
| Drug class | Carbohydrate supplement; hypertonic dextrose solution |
| Modality | Small molecule |
| Therapeutic area | Endocrinology; Critical Care; Supportive Care |
| Phase | FDA-approved |
Mechanism of action
When administered intravenously, the 20% glucose solution delivers a concentrated source of dextrose that is rapidly absorbed into the bloodstream, raising serum glucose levels. This serves to correct hypoglycemia, provide immediate caloric support, and supply glucose substrate for cellular energy production (ATP synthesis) via glycolysis and aerobic metabolism.
Approved indications
- Acute hypoglycemia (symptomatic or severe)
- Caloric supplementation in parenteral nutrition
- Adjunctive treatment in hyperkalemia (shifts potassium intracellularly)
Common side effects
- Hyperglycemia
- Phlebitis or thrombophlebitis (at infusion site)
- Osmotic diuresis
- Rebound hypoglycemia
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (PHASE1, PHASE2)
- Dexmedetomidine for Invasive Ventilation In the NEOnate (PHASE2, PHASE3)
- Gestational Diabetes and Pharmacotherapy (GAP) (PHASE4)
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (PHASE2)
- Comparative Effects of Periodized Circuit Training and Conventional Strength Training in Patients With Diabetes Type II (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |